AIMS/HYPOTHESIS: Dysregulated expression of metabolic and inflammatory genes is a prominent consequence of obesity causing insulin resistance and type 2 diabetes. Finding causative factors is essential to understanding progression of these pathologies and discovering new therapeutic targets. The transcription factor V-maf musculoaponeurotic fibrosarcoma oncogene homologue B (MAFB) is highly expressed in human white adipose tissue (WAT). However, its role in the regulation of WAT function is elusive. We aimed to characterise MAFB expression and function in human WAT in the context of obesity and insulin resistance. METHODS: MAFB mRNA expression was evaluated in human WAT from seven cohorts with large inter-individual variation in BMI and metabolic features. Insulin-induced adipocyte lipogenesis and lipolysis were measured and correlated with MAFB expression. MAFB regulation during adipogenesis and the effects of MAFB suppression in human adipocytes was investigated. MAFB regulation by TNF-α was examined in human primary adipocytes and THP-1 monocytes/macrophages. RESULTS: MAFB expression in human adipocytes is upregulated during adipogenesis, increases with BMI in WAT, correlates with adverse metabolic features and is decreased after weight loss. MAFB downregulation decreases proinflammatory gene expression in adipocytes and interferes with TNF-α effects. Interestingly, MAFB is differentially regulated by TNF-α in adipocytes (suppressed) and THP-1 cells (upregulated). Further, MAFB is primarily expressed in WAT macrophages/monocytes and its expression correlates with macrophage and inflammatory markers. CONCLUSIONS/ INTERPRETATION: Our findings indicate that MAFB is a regulator and a marker of adipose tissue inflammation, a process that subsequently causes insulin resistance.
AIMS/HYPOTHESIS: Dysregulated expression of metabolic and inflammatory genes is a prominent consequence of obesity causing insulin resistance and type 2 diabetes. Finding causative factors is essential to understanding progression of these pathologies and discovering new therapeutic targets. The transcription factor V-maf musculoaponeurotic fibrosarcoma oncogene homologue B (MAFB) is highly expressed in human white adipose tissue (WAT). However, its role in the regulation of WAT function is elusive. We aimed to characterise MAFB expression and function in human WAT in the context of obesity and insulin resistance. METHODS:MAFB mRNA expression was evaluated in human WAT from seven cohorts with large inter-individual variation in BMI and metabolic features. Insulin-induced adipocyte lipogenesis and lipolysis were measured and correlated with MAFB expression. MAFB regulation during adipogenesis and the effects of MAFB suppression in human adipocytes was investigated. MAFB regulation by TNF-α was examined in human primary adipocytes and THP-1 monocytes/macrophages. RESULTS:MAFB expression in human adipocytes is upregulated during adipogenesis, increases with BMI in WAT, correlates with adverse metabolic features and is decreased after weight loss. MAFB downregulation decreases proinflammatory gene expression in adipocytes and interferes with TNF-α effects. Interestingly, MAFB is differentially regulated by TNF-α in adipocytes (suppressed) and THP-1 cells (upregulated). Further, MAFB is primarily expressed in WAT macrophages/monocytes and its expression correlates with macrophage and inflammatory markers. CONCLUSIONS/ INTERPRETATION: Our findings indicate that MAFB is a regulator and a marker of adipose tissue inflammation, a process that subsequently causes insulin resistance.
Authors: Isabella Artner; John Le Lay; Yan Hang; Lynda Elghazi; Jonathan C Schisler; Eva Henderson; Beatriz Sosa-Pineda; Roland Stein Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Anna Ehrlund; Niklas Mejhert; Christel Björk; Robin Andersson; Agné Kulyté; Gaby Åström; Masayoshi Itoh; Hideya Kawaji; Timo Lassmann; Carsten O Daub; Piero Carninci; Alistair R R Forrest; Yoshihide Hayashizaki; Albin Sandelin; Erik Ingelsson; Mikael Rydén; Jurga Laurencikiene; Peter Arner; Erik Arner Journal: Diabetes Date: 2016-11-01 Impact factor: 9.461
Authors: Johanna Säll; Annie M L Pettersson; Christel Björk; Emma Henriksson; Sebastian Wasserstrom; Wilhelm Linder; Yuedan Zhou; Ola Hansson; Daniel P Andersson; Mikael Ekelund; Eva Degerman; Karin G Stenkula; Jurga Laurencikiene; Olga Göransson Journal: Diabetologia Date: 2016-11-02 Impact factor: 10.122
Authors: Maryam Khoshnejat; Kaveh Kavousi; Ali Mohammad Banaei-Moghaddam; Ali Akbar Moosavi-Movahedi Journal: BMC Med Genomics Date: 2020-08-24 Impact factor: 3.063